Myriad Genetics at 41st Annual J.P. Morgan Healthcare Conference

Paul J. Diaz, president and chief executive officer, Bryan Riggsbee, chief financial officer, and Dale Muzzey, chief scientific officer, presented at the 41st Annual J.P. Morgan (JPM) Healthcare Conference on Monday, Jan. 9, 2023.

Q3 2022 Earnings

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, hosted its third-quarter earnings conference call on Tuesday, Nov. 1, 2022.

Events & Presentations

  • 11/01/2022

    Myriad Genetics Third Quarter 2022 Financial Earnings

  • 08/04/2022

    Myriad Genetics Second Quarter 2022 Financial Earnings Call

  • 05/11/2022

    BofA Securities 2022 Healthcare Conference

Latest News

Myriad Genetics Reports Third Quarter Financial Results

November 1, 2022

Click here for presentation. Highlights: Revenue of $156.4 million for the quarter ended September 30, 2022. Third quarter revenue, excluding div...

Family Cancer History Still a Mystery to Many Women

September 28, 2022

Results from a nationwide survey conducted on the attitudes, knowledge, and practices related to risk assessment, prevention, and screening for breast and ovari...

Myriad Genetics to Share Update on Business Transformation, Research and Development Pipeline, and Growth Plans at Investor Day on Aug. 11, 2022

July 19, 2022

Myriad Genetics, Inc., (NASDAQ: MYGN), will host an Investor Day on Aug. 11, 2022, providing a strategic business update and overview of the company’s growth ...

Stock Information



-0.82 (-3.95)










Financial Reports and Filings

  • 01/31/2023 SC 13G/A

    An amendment to the SC 13G filing
  • 01/23/2023 4

    Statement of changes in beneficial ownership of securities
  • 01/23/2023 SC 13G/A

    An amendment to the SC 13G filing

Our ESG Story

“For more than 31 years, Myriad Genetics has worked to be a force for good in the world as we fulfill our mission to advance health and well-being for all. In our inaugural ESG report, we seek to convey our core values as a caring, ethical, and sustainable company committed to continuous improvement,” said Paul J. Diaz, president and CEO, Myriad Genetics. “I want to thank our 2,400 teammates for the progress we have made to date, recognizing we have more work to be done. We are committed to intensifying our ESG focus helping to address the needs of the patients, healthcare providers, stakeholders, and communities we serve.”

Screen Shot 2022-08-01 at 2.32.33 PM